

A cost-effective insulin pen needle without compromise on quality, supported by our FREE implementation service.

- In line with NHS recommendations to spend less than £5 per box, Insupen Original is priced at £2.49 per pack (100 needles)<sup>1</sup>.
- Average CCG/Health Board pen needle savings of 43% per annum<sup>2</sup>.
- 700% greater savings when actively implemented using our managed formulary change model<sup>3</sup>.

Contact Spirit to understand how we help CCGs and Health Boards deliver prescribing savings.





## INSUPEN Original

# **Available in:** 5 lengths and 5 gauges

47% of people with diabetes would be more likely to follow their prescribed regimen if injections were less painful<sup>6</sup>.

PIP CODE
421-4664
415-5313
415-5321
415-5339
415-5347
415-5354
415-5362
415-5370
415-5578

£2.49 per pack of 100



Universal fit - for use with any standard insulin pen.

### **Benefits for your patients**

#### **Quality Assured**

Insupen Original insulin pen needles conforms to ISO 11608 and additional quality checks<sup>4</sup>.

#### **Comfort**

Precision engineered to reduce friction points and reduce pain<sup>4,5</sup>.

Wide internal diameter for efficient insulin flow and administration<sup>4</sup>.

#### **Choice**

Choose from 5 lengths and 5 gauges to match patient need.



#### References:

- 1. Items which should not routinely be prescribed in primary care: Guidance for CCGs version 2, June 2019 NHS England Publishing Approval Reference 000608
- 2. Insulin Pen Needle cost model evaluation. Data on file, Spirit Healthcare, December 2021
- 3. Jim Swift et al, "Implementing formulary change in diabetes", British Journal of Healthcare Management, Vol. 23, No. 4
- 4. Data on file, Spirit Healthcare. Pikdare quality standards and testing data, supplied April 2020
- 5. Comparison of usability and Patient Preference for insulin Pen Needles produced with different production Techniques:"Thin-Wall" Needles compared to "Regular-Wall" Needles: An Open-Label Study, Thorsten Siegmund, M.D., Hannes Blankenfeld, M.D., and Petra-Maria Schumm-Draeger, M.D., Diabetes Technology & Therapeutics. August 2009,11 (8):523-528. doi: 10.1089/dia. 2009. 0048. Published in Volume: 11 Issue 8: August 21, 2009
- 6. AADE Injection Impact Survey, 2007.

**Approval number:** HEA4172MAY22



24/7 NON-AUTOMATED FREE SUPPORT **0800 881 5423** 

Spirit Family of Companies Spirit House, Saffron Way Leicester, LE2 6UP T: 0116 286 5000 www.spirit-health.com meds-op@spirit-health.com